ERAS Erasca, Inc.
Price Chart
Executive Summary
Erasca has entered into a clinical trial collaboration with Tango Therapeutics to evaluate its pan-RAS molecular glue ERAS-0015 in combination with Tango's PRMT5 inhibitor vopimetostat for treating MTAP-deleted RAS-mutant cancers. Erasca will supply ERAS-0015 at no cost, while Tango will sponsor the Phase 1/2 trial. The partnership targets a high unmet need in pancreatic and NSCLC cancers with a dual-pathway inhibition strategy.
Actionable Insight
Monitor early combination trial data for signs of enhanced efficacy over monotherapy; assess whether responses in MTAPdel RASm tumors validate the dual-inhibition hypothesis. This collaboration de-risks Erasca’s development spend while expanding ERAS-0015’s clinical footprint.
Key Facts
- Erasca and Tango Therapeutics announced a clinical trial collaboration to evaluate ERAS-0015 (Erasca) + vopimetostat (Tango) in MTAP-deleted RAS-mutant pancreatic and NSCLC cancers.
- Tango will sponsor the Phase 1/2 trial; Erasca will supply ERAS-0015 at no cost.
- Each company retains full commercial rights; the agreement is non-exclusive.
- Preclinical data suggest ERAS-0015 has 5x greater RAS inhibition potency and up to 21x higher CypA binding affinity vs. RMC-6236.
- ERAS-0015 showed early clinical responses at 8 mg QD in multiple tumor types with different RAS mutations.
Financial Impact
No direct financial outlay from Erasca; potential long-term value creation if combination shows efficacy
Risk Factors
- Combination may not show synergistic efficacy despite strong preclinical rationale
- Safety concerns could emerge with dual pathway inhibition
- Unconfirmed partial responses in monotherapy may not mature into confirmed responses
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250024 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
Institutional Cluster
| $14.03 awaiting T+5 | awaiting T+5 | — | $14.05 (+0.18%) |
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $13.70 awaiting T+5 | awaiting T+5 | — | $14.05 (+2.55%) |
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $13.13 awaiting T+5 | awaiting T+5 | — | $14.05 (+7.01%) |
|
May 11, 2026
4w ago
|
Press Release
| $10.44 $10.27 | ▼ −1.63% | ▼ −1.54% | $14.05 (+34.58%) |
|
Apr 28, 2026
6w ago
|
DEFA14A
| $9.11 $9.99 | ▲ +9.66% | ▲ +6.55% | $14.05 (+54.23%) |
|
Apr 27, 2026
6w ago
|
8-K
| $9.90 $10.14 | ▲ +2.42% | ▲ +0.73% | $14.05 (+41.92%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $9.90 $10.14 | ▲ +2.42% | ▲ +0.73% | $14.05 (+41.92%) |
|
Apr 27, 2026
6w ago
|
8-K
| $19.15 $10.14 | ▼ −47.05% | ▼ −47.45% | $14.05 (−26.63%) |
|
Apr 21, 2026
7w ago
|
8-K
| $22.41 $9.90 | ▼ −55.82% | ▼ −56.91% | $14.05 (−37.30%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $13.62 $14.60 | ▲ +7.20% | ▲ +9.31% | $14.05 (+3.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access